Literature DB >> 1800117

Pharmacological properties of a novel class of 5-HT3 receptor antagonists.

M Turconi1, A Donetti, A Schiavone, A Sagrada, E Montagna, M Nicola, R Cesana, C Rizzi, R Micheletti.   

Abstract

The pharmacological profile of six representative members of a novel class of 5-HT3 receptor antagonists is described. The compounds are esters and amides of benzimidazolone-1-carboxylic acid with a basic azabicycloalkyl moiety (compounds 1-3) and their respective ethyl derivatives (compounds 4-6). In isolated preparations (rabbit heart and guinea pig ileum) all compounds antagonized the 5-HT3 receptor-mediated effects of serotonin, with potencies comparable with those of the reference compounds, ICS 205.930 and GR 38032F (-log IC50 9.30-11.9 and 6.8-8.20, in heart and ileum, respectively). In the anaesthetised rat, all agents potently inhibited the Bezold-Jarisch reflex whether given i.v. or i.d. I.v. administration of compounds prevented cisplatin-induced emesis in dogs (ID50 ranging from 3.7 to 147 micrograms/kg). All agents accelerated gastric emptying of solids in rats (ED50 about 10-160 micrograms/kg i.p.). In addition, compounds 4 and 5 were able to stimulate 5-HT4 receptors in the isolated guinea pig ileum, as well as enhance contractile activity in the Heidenhain gastric pouch of dogs, showing clearcut prokinetic properties.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1800117     DOI: 10.1016/0014-2999(91)90716-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Identification of Potent and Selective Inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PfM18AAP) of Human Malaria via High-Throughput Screening.

Authors:  Timothy Spicer; Virneliz Fernandez-Vega; Peter Chase; Louis Scampavia; Joyce To; John P Dalton; Fabio L Da Silva; Tina S Skinner-Adams; Donald L Gardiner; Katharine R Trenholme; Christopher L Brown; Partha Ghosh; Patrick Porubsky; Jenna L Wang; David A Whipple; Frank J Schoenen; Peter Hodder
Journal:  J Biomol Screen       Date:  2014-03-11

2.  Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors.

Authors:  C A Rizzi; A Sagrada; A Schiavone; P Schiantarelli; R Cesana; G B Schiavi; H Ladinsky; A Donetti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-04       Impact factor: 3.000

3.  Characterization of a novel 5-HT4 receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285.

Authors:  A Dumuis; H Gozlan; M Sebben; H Ansanay; C A Rizzi; M Turconi; E Monferini; E Giraldo; P Schiantarelli; H Ladinsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

4.  Effects of DAU 6215, a novel 5-hydroxytryptamine3 (5-HT3) antagonist on electrophysiological properties of the rat hippocampus.

Authors:  M B Passani; A M Pugliese; M Azzurrini; R Corradetti
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

5.  The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors.

Authors:  A Lucchelli; M G Santagostino-Barbone; A Barbieri; S M Candura; M Tonini
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

6.  Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation.

Authors:  A Sagrada; M Turconi; P Bonali; P Schiantarelli; R Micheletti; E Montagna; M Nicola; D R Algate; E M Rimoldi; A Donetti
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.